Accendra Health Reports $627.8 Million Revenue, Net Loss Narrows to $6.5 Million

Accendra Health, Inc. reported a net revenue of $627.8 million for the three months ended March 31, 2026, a decrease of 6.8% from $673.9 million in the same period of the previous year. The decline in revenue was primarily attributed to a $42 million drop in sales linked to terminated contracts with a commercial payor, which significantly impacted several product categories, including sleep therapy and home respiratory therapy. The company recorded an operating income of $17.1 million, down from $19.8 million a year earlier, while the net loss narrowed to $6.5 million, compared to a loss of $25 million in the prior year.

Operating costs and expenses decreased to $610.7 million from $654.1 million, driven by a reduction in selling, general, and administrative expenses, which fell to $255.2 million from $262.4 million. The company also reported a significant decrease in exit and realignment charges, which shifted from a cost of $13.6 million in the previous year to a gain of $23.6 million in the current period, largely due to gains from the sale of patient service equipment. However, interest expenses rose to $32.3 million from $24.2 million, reflecting increased borrowing costs.

In terms of strategic developments, Accendra Health completed the sale of its Products and Healthcare Services (P&HS) business on December 31, 2025, for $375 million, retaining a 5% equity interest. This divestiture has allowed the company to focus on its core operations, which now comprise a single operating segment. The company is also in the process of executing a Balance Sheet Optimization Transaction, which includes refinancing existing debt and extending maturities to improve liquidity.

Operationally, Accendra Health's cash and cash equivalents increased to $336.9 million as of March 31, 2026, up from $282 million at the end of 2025. Accounts receivable also rose to $103.7 million, indicating improved collection efforts. The company sold $246 million in accounts receivable under its Amended Receivables Sale Program during the quarter, collecting $231 million of that amount. The company’s employee headcount remained stable, with no significant changes reported.

Looking ahead, Accendra Health anticipates that the Balance Sheet Optimization Transaction will enhance its liquidity and financial flexibility, allowing it to meet upcoming obligations. The company expects to continue focusing on operational efficiencies and strategic initiatives to drive growth, despite the challenges posed by market conditions and competitive pressures. Management remains optimistic about the company's ability to navigate these challenges and improve its financial performance in the coming quarters.